Erik Nordkamp has been appointed managing director and head of Global Innovative Pharmaceutical business at Pfizer UK, taking over from Jonathan Emms who has been appointed global marketing lead for Pfizer's Global Established Pharmaceutical business. Mr Nordkamp joined Pfizer in 2010 and for the past year has led the firm's Greece, Cyprus and Malta, and the Global Innovative Pharmaceutical business. Prior to this, he worked for Pfizer in the UK as head of strategy for Primary Care Europe and Canada. Erik also served as president of PhRMA Innovation, a trade association, where he led the transformation of the forum, positioning it as the main representative body for the innovative pharmaceutical industry in Greece.
Pfizer UK appoints new MD
Listen to this article
Erik Nordkamp has been appointed managing director and head of Global Innovative Pharmaceutical business at Pfizer UK, taking over from Jonathan Emms who has been appointed global marketing lead for Pfizer's Global Established Pharmaceutical business. Mr Nordkamp joined Pfizer in 2010 and for the past year has led the firm's Greece, Cyprus and Malta, and the Global Innovative Pharmaceutical business. Prior to this, he worked for Pfizer in the UK as head of strategy for Primary Care Europe and Canada. Erik also served as president of PhRMA Innovation, a trade association, where he led the transformation of the forum, positioning it as the main representative body for the innovative pharmaceutical industry in Greece.
Keep up with the top pharma business news of the week. On the go.
More from Business
- • By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
- • By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
More from Scrip
- Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
